Pricing Log in Create free account
Friday 6 November 2026 Export LEGN’s income statement to Excel — free account

Legend Biotech Corporation Sponsored ADR

LEGN Healthcare Biotechnology

Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.

Revenue
+51.9%
EPS
+126.1%
Free cash flow
−26.8%
Total debt
−49.6%

Quarter to June 2026, against a year earlier

23.45 0.91 +4.04%
Market cap
$4.4B
P/E
0.0×
Fwd P/E
−2,029×
Dividend yield
—
F-score
3/9
Altman Z
4.54
Beneish M
−2.08
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Legend Biotech Corporation Sponsored ADR (LEGN) Price to free cash flow

Alert me on Price to free cash flow

Legend Biotech Corporation Sponsored ADR has no meaningful price to free cash flow: its trailing twelve-month free cash flow is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
23 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

Price to free cash flow against peers

Company Price to free cash flow
EWTX Edgewise Therapeutics, Inc. compare n/m
LEGN Legend Biotech Corporation Sponsored ADR n/m
DFTX Definium Therapeutics, Inc. compare n/m
ERAS Erasca, Inc. compare n/m
DNTH Dianthus Therapeutics, Inc. compare n/m
CRSP CRISPR Therapeutics AG compare n/m
RLAY Relay Therapeutics, Inc. compare n/m
COGT Cogent Biosciences, Inc. compare n/m
TVTX Travere Therapeutics, Inc. compare 55.3×
Biotechnology industry median 25.2×
Healthcare sector median 20.5×
Market median 14.0×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on LEGN